Baxter International (BAX) Osake Kurssi
Baxter International Kurssi
Viimeisten 19 vuoden aikana Baxter Internationaln liikevaihto kasvoi 0,4 % vuodessa ja ylsi 11,24 Mrd. USD:een. Osakekohtainen tulos on kasvanut 5,5 % vuodessa viimeisten 17 vuoden aikana. Baxter Internationaln nettomarginaali −8,5 % on laskenut verrattuna 10,6 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 2,07 %. Baxter Internationaln 12 kuukauden konsensustavoitehinta on 25,00 USD, noin ali kurssia 0,4 %. 20 analyytikosta 5 suosittaa ostoa — kokonaiskonsensus on Pidä.
Baxter International osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Baxter International liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Baxter International -osakkeesta
The business model of Baxter International Inc. is centered around developing, manufacturing, and marketing a broad portfolio of products and therapies for patients with life-threatening medical conditions. Baxter provides essential healthcare solutions across the clinical areas of critical care, nutrition, renal, and pharmaceuticals. The company's products and services aim to support healthcare professionals in improving patient outcomes and enhancing overall medical care. Baxter International Inc. operates globally and collaborates with various stakeholders in the healthcare industry to deliver innovative solutions that address unmet medical needs.
Baxter International Inc is primarily active in the healthcare industry. As a global leader in medical technology, Baxter specializes in providing innovative solutions for hospitals, clinics, and home care settings. The company focuses on various segments within healthcare, including renal care, acute therapies, and medication delivery. With a wide range of products and services, Baxter plays a vital role in enhancing patient care and improving outcomes across the healthcare continuum.
The main competitors of Baxter International Inc in the market include Johnson & Johnson, Fresenius Medical Care AG & Co. KGaA, and Becton, Dickinson and Company.
Baxter International Inc., based in Deerfield, Illinois, is a renowned American healthcare company with a rich history and impressive background. Established in 1931, Baxter has consistently excelled in developing and manufacturing medical products and technologies, specializing in biotherapeutics, renal care, and medication delivery. With a commitment to advancing patient care, Baxter has grown to become a global leader in the healthcare industry. Over the years, the company has introduced numerous innovative and life-saving solutions, including intravenous therapies, vaccines, and devices for dialysis. With its dedication to meeting critical healthcare needs worldwide, Baxter International Inc. continues to be a prominent player in the medical field.
Over the years, Baxter International Inc has achieved numerous significant milestones, solidifying its position in the healthcare industry. One notable achievement is the development of innovative medical products and therapies that have improved patient outcomes globally. Baxter International Inc has also demonstrated its commitment to sustainability by implementing eco-friendly practices and receiving recognition for its environmental efforts. Additionally, the company has expanded its international presence through strategic acquisitions and collaborations, further strengthening its global footprint. Overall, Baxter International Inc's dedication to innovation, sustainability, and global expansion has propelled it to become a leading player in the healthcare sector.
Baxter International Inc is primarily present in numerous countries and regions globally. This healthcare company operates in North America, including the United States, Canada, and Mexico. It has a strong presence in Europe, spanning countries like Germany, France, Italy, and the United Kingdom. Baxter International Inc also has significant operations in the Asia-Pacific region, with a focus on countries such as China, Japan, India, and Australia. Additionally, the company maintains a presence in Latin America, including Brazil, Argentina, and Chile. With its extensive global reach, Baxter International Inc serves a diverse range of markets and communities worldwide.
Baxter International Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on improving patient outcomes, the company strives to provide high-quality healthcare products and services worldwide. Baxter International Inc is committed to advancing medicine through its diverse portfolio of medical devices, pharmaceuticals, and biotechnology solutions. As a global leader, Baxter International Inc consistently emphasizes ethical practices, regulatory compliance, and sustainability. By actively investing in research and development, Baxter International Inc aims to drive positive changes in healthcare and enhance the well-being of patients globally.
Analyytikot asettavat tällä hetkellä Baxter International-osakkeelle keskimääräisen tavoitehinnan 25,00 USD (mediaani: 25,00 USD), mikä merkitsee −0,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.
20 analyytikkoa arvioi tällä hetkellä Baxter International-osaketta: 5 suosittaa ostoa, 14 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Baxter International-yhtiöltä 11,62 Mrd. USD liikevaihtoa ja 2,04 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Baxter International-osake noteerataan hintaan 22,37 EUR (25,09 USD).
Baxter International-osake (BAX) on listattuna 11 pörssissä, muun muassa: NYSE (BAX), London (0QK8.L), SIX (Zürich) (BAX.SW), XETRA (BTL.DE), Frankfurt (BTL.F), München (BTL.MU), Düsseldorf (BTL.DU), Hamburg (BTL.HM).
Baxter International Inc is a US-based company operating in the healthcare and pharmaceutical sectors. The company provides medical products and services to supply patients worldwide. It is divided into three main business segments: Hospital Products, Renal Products, and Clinical Nutrition. Hospital Products is the largest segment and offers a variety of products including infusion solutions, injectables, medical devices, and concentrated solutions. Renal Products includes products and services for dialysis treatment, home hemodialysis, and acute kidney failure. Baxter also manufactures dialysis machines and accessories, as well as dialysis containers and concentrates. Clinical Nutrition also offers specialized nutrition products and preparations for parenteral nutrition. The company is a leading provider of parenteral nutrition products, including amino acids, carbohydrates, fat emulsions, and electrolytes. Baxter International also manufactures blood products such as plasma products and clotting factors. Additionally, the company offers specially processed biological products that can be used to treat conditions such as hemophilia and immunodeficiency. The company also operates an advanced life sciences business focused on drug development and medical devices. Baxter International collaborates with numerous global partners and develops innovative technologies in oncology and other areas of medical research. Baxter International is a company focused on proactive solutions to improve patient care and provide safe, effective, and high-quality medical products. The company is also committed to sustainable development and environmental protection by optimizing its materials and energy sources and continuously improving its production technology. In summary, Baxter International is a company dedicated to the development and provision of high-quality medical products and services. Through its various business segments, the company offers a wide range of products and services for different medical conditions to improve the medical care of patients worldwide. The company has also committed to sustainable and environmentally friendly production to fulfill its responsibility to society and the environment.
odotettu liikevaihto Baxter International on 11,62 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Baxter International on 1,05 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Baxter International:n hinta-voitto-suhde (P/E) on tällä hetkellä 12,33. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Baxter International-osakkeen arvostusta.
Baxter International:n hinta-myynti-suhde (P/S) on tällä hetkellä 1,11. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Baxter International-osakkeen arvostuskennuslukuna.
Baxter International:n Eulpool-laatuscore on 1/10.
Baxter International:n ISIN on US0718131099. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Baxter International:n WKN on 853815. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Baxter International:n ticker on BAX. Tämä pörssinoteeraus käytetään Baxter International-osakkeiden kauppaan pörssissä.
Baxter International osake
Baxter International vertaisryhmä
Baxter International Ticker
Baxter International FIGI
Kaikki tunnusluvut ja syvällinen analyysi Baxter International:sta
Meidän osakeanalyysimme Baxter International-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Baxter International:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: